This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biotie Therapies Corp.
Drug Names(s): SYN117, SYN-117
Description: SYN-117 is a competitive and selective inhibitor of the enzyme dopamine beta-hydroxylase (DBH). Inhibition increased dopamine in the central nervous system. Of note, one study has found DBH activity higher in patients with post-traumatic stress disorder with psychotic features than with non-psychotic features.
Deal Structure: SYN-117 was originally developed by Roche.
Roche and Synosia
In January 2007, Roche and Synosia entered a partnership in which Synosia will acquire five drug candidates from Roche, including SYN-117. Under the terms of the agreement, Synosia will assume responsibility for the clinical development of the five drug candidates, including SYN-117. Roche retains the right to opt-in to potential products resulting from two of these programs on completion of agreed milestones. Synosia retains full commercial rights to three pre-selected programs and can bring these products to market either alone or with a partner.
In March 2009, Synosia announced it has entered into a second agreement with Roche, extending the partnership to include a second 5-HT6 antagonist and also revising the terms of the original agreement to give Synosia full development and commercialisation rights to all programmes. Roche retains opt-in rights to the 5-HT6 programme only.
Biotie and...See full deal structure in Biomedtracker
Additional information available to subscribers only: